Novo Holdings silent on insider trading case

A representative for the Novo Nordisk owner has refused to say whether the company received insider trading information about Convatec from the company’s former chairman, who has been fined for his involvement.

It is still unclear whether Novo Holdings was one of the shareholders that received confidential information about medtech firm Convatec | Photo: Novo Holdings / PR

Novo Holdings, the owner of Danish pharmaceutical firm Novo Nordisk, is tight-lipped when it comes to the insider trading case surrounding Sir Christopher Gent, former chairman of British medtech firm Convatec, reports Danish business media Børsen.

The Danish investment company bought a share of just under 20% in Convatec for nearly DKK 9bn (USD 1.2bn) in March 2017, and is today represented on the board by former chairman of the Novo Nordisk Foundation Sten Scheibye, who also served as CEO of Coloplast, a competitor to Convatec in several areas.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs